Jazz Pharmaceuticals Submits Marketing Authorization Application to European Medicines Agency for Solriamfetol as a Treatment to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adult Patients with Narcolepsy or Obstructive Sleep Apnea
DUBLIN, Nov. 9, 2018 -- (Healthcare Sales & Marketing Network) -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for solriamfetol, a selective dopamine... Biopharmaceuticals, Regulatory Jazz Pharmaceuticals, solriamfetol, narcolepsy, obstructive sleep apnea
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: European Medicines Agency (EMA) | Marketing | Narcolepsy | Obstructive Sleep Apnea | Pharmaceuticals | Sleep Apnea | Sleep Disorders | Sleep Medicine